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RHEUMATIC MITRAL STENOSIS WITH LEFT ATRIAL 
APPENDAGE THROMBUS – EFFECT OF ORAL 
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THROMBUS RESOLUTION
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AF- Atrial fibrillation                                       AF-I- Intermittent atrial fibrillation
ACC –American College of cardiology           AHA- American Heart Association
 TTE-Transthoracic echocardiography            TEE-Transesophageal echocardiography
MS-Mitral stenosis                                           MR-Mitral regurgitation
TR-Tricuspid regurgitation                              AR –Aortic regurgitation
TS-Tricuspid stenosis                                       MV -Mitral valve 
LA-Left atrium                                                 LV-Left ventricle
LAA-Left atrial appendage                              PG-Peak gradient; MG-mean gradient
PLAX- Parasternal long axis                           PSAX-Parasternal short axis
A4C- Apical four chamber view                      SEC-Spontaneous echo contrast
LASEC Left atrial Spontaneous echo contrast   PHT-Pulmonary hypertension 
EF-Ejection fraction                                            INR- International normalized ratio 
SD-Standard deviation                                         NYHA- New York Heart Association 
CMC-Closed mitral commissurotomy                BMV- Balloon mitral Valvotomy
PTMC-Percutaneous Transluminal mitral commissurotomy
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INTRODUCTION
             Rheumatic heart disease is one of the commonest cardiac condition in India in both children 
and adults, accounting for 30- 40 % of cardiac cases admitted in hospital. Approximately 25% of all 
patients  with  rheumatic  heart  disease  have  pure  or  predominant  mitral  stenosis  (MS). 
Thromboembolism develops in at least 20% of mitral stenosis patients, at some point of time during the 
course of their disease. Thromboembolism remains an important cause of morbidity and mortality in 
rheumatic MS.
              Cardiogenic embolism in mitral stenosis is most often due to left atrial (LA) thrombi and at  
times due to mitral valve vegetation. Left atrial appendage (LAA) is the commonest site from where 
the thrombus originates.
             Echocardiography is the widely used method for detecting left atrial and left atrial appendage  
thrombi.  Transthoracic  echocardiography  (TTE)  is  only  50% sensitive  in  detecting  LA and  LAA 
thrombi.  Transesophageal  echocardiography (TEE)  is  superior  to  TTE and   is  99% sensitive and 
specific in detecting LA and LAA thrombi.
              Left atrial spontaneous echo contrast (LASEC) or “Smoke” occurs in conditions that favours  
stasis  of  blood  .It  is  associated  with  an  increased  risk  of  LA thrombus  formation  and  arterial  
embolization and is better identified by TEE.
             Medical treatment for LA and LAA thrombus in rheumatic MS is still unclear. Several studies  
indicate that adequate anticoagulation using oral anticoagulants in those with atrial fibrillation and in 
those with documented thrombus reduce the frequency of thromboembolic phenomena.
             However there are not enough data whether anticoagulation resolves or reduces size of LA 
thrombus  in  patients  with  rheumatic  MS,  and  thus  simplifying  hence  simplifying  surgical  or 
interventional treatment for diseased valves otherwise suitable for closed mitral comissurotomy (CMC) 
or balloon mitral valvotomy (BMV).
AIM OF THE STUDY
             Left atrial (LA) thrombus formation remains a significant problem causing   morbidity and 
mortality in rheumatic mitral stenosis.
              Medical treatment for this condition still remains unclear. This study is aimed 
            1. To study the effect of oral anticoagulation on resolution of left atrial appendage thrombus.
            2. To analyse various factors associated with resolution or reduction in size of 
            left atrial appendage thrombus.
            3. To analyse effect of oral anticoagulation on left atrial spontaneous 
            echo contrast. 
BACKGROUND
             Rheumatic heart disease remains one of the commonest acquired heart diseases affecting young 
and middle aged population in our country.
           Pure or predominant Mitral stenosis (MS) is the commonest presenting manifestation of chronic  
rheumatic heart disease accounting for 25%   percentage of all cases.  Females outnumber males by two 
fold, affected by rheumatic MS.
           Left atrial thrombus formation is an important complication of rheumatic MS causing morbidity  
and mortality.
         In one study 17% of patients undergoing surgery for mitral stenosis have left atrial thrombus and 
in about two third of these patients, the thrombus is restricted to left atrial appendage (LAA).
         Deverall  et al.1 reported that 16% of patients evaluated for MS had a history of systemic 
embolism. 
        In approximately 10-15% of patients with MS systemic embolic manifestation due to left atrial 
thrombus may be the first symptom. Cerebral embolism constitutes 60-70 % of episodes of systemic 
embolism in several series.
       Emboli are often fatal in patients with mitral stenosis. In a 10 year follow-up of 250 patients with 
unoperated MS, Rowe et al2, found that 19% of 110 deaths in the first 10 years of follow-up are due to 
systemic  embolism.  In  the  follow-up  series  of  Olesen3,  22%  of  all  deaths  in  MS  were  due  to 
thromboembolism.
    Several studies reported that the following factors are associated with left atrial thrombus formation 
in MS.
          1. Atrial fibrillation
          2. Age-Higher the age, greater the risk.
          3. Left atrial size.
          4. Left atrial spontaneous echo contrast.
          5. LV systolic dysfunction 
              The severity of mitral stenosis does not correlate with risk of thrombus formation.
            On the other hand presence of significant mitral regurgitation is a negative predictor of  
development of left atrial thrombus .This may be due to an increase in flow velocity with in left atrium 
in systole created by MR. 
              In the classical series of Coulshed et al4, 737 patients with predominant mitral stenosis were 
followed up for cardiac events. Of 248 patients .0f 35 years or less,  the incidence of embolisation was  
9% .Of 489 patients over 35 years ,the incidence was 24%.  Deveral et al1, found that incidence of 
systemic emboli correlates better with years since initial rheumatic activity than chronological age per 
se.
ATRIAL FIBRILLATION (AF)
                        Atrial  fibrillation  is  another  important  factor  associated  with  left  atrial 
thrombus .Most of the MS patients who have systemic embolism are in AF. The prevalence of AF 
increases with age.
            Eighty percent of patients with MS, in whom systemic emboli develop, are in atrial fibrillation  
(AF). The combination of MS and AF increases the chances of stroke 17 fold. 
           There is seven time greater risk of stroke in patients with MS in AF, when compared with those  
with MS in sinus rhythm (SR).  Just the presence of MS and AF, is said to confer the greatest risk for  
thromboembolism.
              In coulshed et al4 .series, in those over 35 years of age, the incidence of systemic embolism 
was 32 % in those with AF as against 11% in those in sinus rhythm.
          When atrial fibrillation supervenes, blood flow in the atrial appendage and in the body of the left  
atrium becomes more disorganised, with low velocity, multidirectional flow patterns, blood flow stasis, 
and development of atrial thrombi.
            This swirling pattern of low velocity flow often is evident as spontaneous echo contrast in  
echocardiography, particularly when using a high frequency transducer from transesophageal approach.
LEFT ATRIAL SIZE
            Left atrial size is assessed by various methods .Most commonly left atrial dimension measured  
by M-mode  in  transthoracic  parasternal  long  axis  (PLAX) at  the  level  of  aortic  valve  level.  The 
measurement is made at end-systole, just before mitral valve opening when the left atrial volume is 
maximal. In addition various studies indicated that left atrial volume is a powerful prognostic factor in 
variety of situations 
                  Left atrial dimensions were measured in end systole in PLAX-antero posterior (D1)and two 
orthogonal  diameters  in four chamber view (D2 & D3) and left  atrial  volume calculated by using 
prolate ellipse method.
          Left atrial volume = (D1 X D2 X D3) X 0.523
              In patients with MS in SR, LA size correlates with the development of AF, and it is  
recommended by ACC and AHA guidelines   that  those with  LA size  greater  than 5.5 cm can be 
prophylactically anticoagulated.  The data on left  atrial  size predisposing LA thrombus formation is 
controversial. Madden et al5, first proposed that increased left atrial size is associated with increased 
risk of systemic embolism, which was supported by Sommerville and Chambers6, who reported a three 
fold increase in embolism in patients with mitral stenosis with enlarged left atrial appendage on chest  
X-ray compared with those who did not. These observations were not supported by subsequent studies, 
including a multifactorial study by Peterson et al7.  
LEFT ATRIAL SPONTANEOUS ECHOCONTRAST (LASEC)
                Spontaneous echo contrast (SEC) or “smoke” is characterised by discrete, dynamic, swirling  
smoke- like echoes, under conditions of low shear rate of flow, i.e.  low velocity gradient between 
adjacent fluid layers.
              SEC probably results from erythrocyte aggregation or rouleaux formation, while some propose 
a role for platelet aggregation.
               Left atrial spontaneous echo contrast   (LASEC), occurs in conditions that favour blood stasis, 
including mitral stenosis , atrial fibrillation and LA enlargement. 80% to100% of patients with LA 
thrombi has LASEC.  
               Of clinical importance LASEC is an independent predictor of thromboembolic risk in patients  
with MV disease, and in non valvular AF. In addition severe “smoke” showed a stronger association 
with LA thrombus and embolism than mild “smoke”.
               Analysis of SEC includes consideration of site, extent, intensity, and whether constant or  
intermittent. Intensity of LA.SEC is usually divided into two grades;  
              Marked SEC, visible at usual operative gain control of the equipment throughout the LA, and 
Mild SEC, appearing only at a high gain setting, in some portions of LA.
                         Though SEC is associated with increased thromboembolic risk, there is no consensus in 
the literature, on what therapy is indicated in patients with LA “smoke.
      Patterns of blood flow in the left atrium are altered by mitral valve obstruction. Flow proximal to  
narrowed orifice accelerates as blood approaches the stenotic orifice, forming a high velocity jet in the 
orifice itself .Flow more distal to valve orifice also is altered.
  ANALYSIS OF PULMONARY VENOUS DOPPLER FLOW IN MS BY TEE
                  Patterns of pulmonary venous Doppler flow are complex and is best visualised by TEE. As 
of now the pulmonary venous flow by Doppler echo, is not significantly variable between the different 
pulmonary veins. 
                Normally the pulmonary venous flow is pulsatile with forward flow in ventricular systole and 
diastole, followed by a backward or reversed flow during atrial systole.  Forward  triphasic flow pattern 
occurs often during normal heart rate ,with two peaks in ventricular systole viz. an early systolic , short 
low velocity jet (S1) (21± 17 cm/s) and a late systolic longer higher velocity jet (S 2 ) ( 55±17 cm/s).
             Forward biphasic flow pattern, occurs especially during sinus tachycardia, with one peak 
during systole (S) and other in diastole (D).
                Normal pattern of pulmonary venous forward flow , manifests peak systolic flow greater than 
or equal to peak diastolic flow (S > D ) ,with peak systolic to diastolic flow velocity ratio >  1).  
Backward flow is characterised by reversal of flow during atrial systole, producing a transient, small 
low velocity jet (A) (17± 5 cm/s).
                  Pulmonary venous Doppler flow pattern is altered by MS, but conflicting data have been 
reported in this regard. 
                 Keran et al8 in 1990, analysed pulmonary venous flow in MS by TTE.
  In mild to moderate MS, the systolic (S) wave was more prominent. The diastolic (D) wave, was  
continuous  throughout  to  end of  diastole,  with  a  low flow shape  and reduced  peak  velocity..   In 
moderate MS, marked retrograde flow into the pulmonary veins (A wave) during atrial systole was 
observed.  In severe MS, Pulmonary vein flow is  decreased during systole,  (S< D) and atrial  flow 
reversal (A) is increased, with the magnitude of these changes corresponding to the degree of elevation 
of left atrial pressure. 
                Even in sinus rhythm, the increased volume of the left atrium leads to low-velocity flow 
patterns, which predispose to development of atrial thrombi, particularly in the left atrial appendage.
               Although the risk of left  atrial  thrombus formation and embolic events is thought to be low 
in MS patients in sinus rhythm, high prevalence of  spontaneous contrast observed in TEE ( upto 45% 
of patients)in this group raises the possibility of a higher embolic risk, even in sinus rhythm, in the 
presence of  mitral stenosis. 
                Some patients in sinus rhythm have demonstrable thrombus, and in some patients with new-
onset atrial fibrillation have LA thrombus suggesting thrombus formation before onset of AF. 
                    The possible mechanism of atrial thrombus formation in sinus rhythm is  the loss of atrial  
appendage mechanical  function  despite  electrical  evidence of  sinus  rhythm, leading to  blood flow 
stasis.
 ASSESSMENT OF LEFT ATRIAL APPENDAGE (LAA) FUNCTION 
              Left atrial appendage is a narrow finger like space, which is elongated and having narrow base  
located at posterolateral aspect of heart. Its size and function 
varies in different individuals. In patients with severe rheumatic MS left atrial appendage enlarges in 
size along with LA enlargement. 
              LAA function is also altered in rheumatic MS, both in sinus rhythm and in atrial fibrillation.  
LAA function is commonly assessed by Doppler and 2D methods. 
By  two  dimensional  multiplane  transesophageal  echocardiography  maximal  and  minimal  LA 
appendage area were measured by planimetry and LAA ejection fraction calculated using formula;
               LAA EF (%) = (LAA. max –LAA .min)/LAA. max   X   100
(LAA. max-Maximal LAA area (end atrial diastole), LAA. Min - Minimum area (end atrial systole)-by 
planimetry.)
            Left atrial appendage function is assessed using pulsed Doppler imaging, with sample volume  
positioned at mouth of the appendage; the maximal velocity during atrial contraction is measured. This 
velocity is  called as LAA peak emptying velocity.  This velocity corresponds to the force of atrial  
appendage contraction or emptying.
           In normal individuals ,left atrial appendage emptying velocity is greater than 50 cm/sec. Low 
left atrial appendage emptying velocity (<20 cm/sec) has been reported to significantly increase the 
embolic risk.            
Significantly  lower  velocities  occur  in  patients  with  atrial  fibrillation,  and  this  finding  has  been 
associated with a predisposition for the development of left atrial appendage thrombus and the risk of 
thromboembolism.
ECHOCARDIOGRAPHIC IMAGING OF LA THROMBUS
                    Conventional transthoracic echocardiography (TTE) has a poor yield in the detection of 
LA appendage thrombi. The sensitivity of TTE in detecting LA appendage clot is at the most 50 %.
             The posterior location of the LA in the chest as well as due to far field and side lobe artifacts  
as well  as  use of  lower frequency transducers  by TTE leads to   the poor visualization of the LA 
appendage contribute to the lack of accuracy of TTE. 
            On the other hand, TEE is an excellent method for detecting atrial thrombi, especially those  
located in the LA appendage.
            This is due to use of higher frequency transducers used in TEE as well as left atrium is a 
posterior structure lying in near field hence producing excellent image quality.
Multiplane TEE allows imaging in numerous views thereby one can confidently diagnose or exclude 
LA and LA appendage thrombi.Infact TEE is 99% sensitive and 99 % specific in identifying left atrial 
thrombi.
                   Echocardiographically left atrial thrombus appear as amorphous, echogenic structure 
adherent to the endocardium whose appearance and texture are distinct from adjacent myocardium. 
They may be in variable shape and may be mobile and multiple.
    An echo-lucent center may be present and it suggests that the thrombus is relatively new and actively 
growing.
            Echocardiography can identify thrombi which are more likely to embolise. Risk factors include 
larger size, increased mobility, protrusion into the cavity of left atrium, heterogenous echo-density with 
echo-lucent center suggesting fresh thrombus. 
            Thrombus dimension ≥ 1.5 cm, history of thromboembolism and mobile thrombus were 
considered as predictors of subsequent embolic events. 
ANTICOAGULATION IN RHEUMATIC MITRAL STENOSIS
Current recommendations for Oral anticoagulation in rheumatic MS include 
   Atrial fibrillation
   Large left atrium > 55 mm
   Left atrial thrombus
   Left atrial spontaneous echo contrast
   Previous embolic manifestations. 
   LV dysfunction EF < 0.30 %
   Hypercoagulable state. 
ACC and AHA recommend oral anticoagulation (INR of 2–3) in patients with mitral valve stenosis and 
paroxysmal or chronic atrial fibrillation and in patients with a history of systemic embolism. In patients  
with  mitral  valve  disease  associated  with  rheumatic  fever,  the  ACCP also  recommends  long-term 
therapy with warfarin sodium (dosage adjusted to prolong the INR to 2–3) in patients who have either  
concurrent paroxysmal or chronic atrial fibrillation or a history of systemic embolism (e.g., stroke).
Patients with rheumatic mitral valve disease and normal sinus rhythm who have a left atrial diameter 
exceeding  5.5  cm also  should  be  considered  for  long-term anticoagulation  because  of  their  high 
likelihood of developing atrial fibrillation.
   Patients with atrial fibrillation who have a breakthrough embolic event despite prophylactic warfarin 
sodium therapy should have the dosage of the drug increased (increase target INR to 3, range: 2.5–3.5) 
or should have aspirin (80–100 mg daily) added to therapy; another oral platelet-aggregation inhibitor 
(dipyridamole, clopidogrel, ticlopidine) may be used if aspirin is not tolerated.
PROBLEMS ASSOCIATED WITH ORAL ANTICOAGULATION THERAPY
          Risk of hemorrhage is closely related to intensity of anticoagulation. Risk of bleeding is higher 
during first month and then decreases gradually owing to the fact
that prothrombin time fluctuates more initially. Other predictions of hemorrhage include poor control of 
degree of anticoagulation, peripheral vascular disease, cerebro- vascular disease, and old age.
        Interaction between oral anticoagulants and other drugs or foods.
         Monitoring of INR.
        Skin necrosis – may be seen between 3rd and 8th day of warfarin therapy, especially in patients of  
protein C and protein S deficiency.
      In these patients, warfarin is contraindicated; the approach is long-term treatment with heparin.
                In patients with severe mitral stenosis , surgical (closed mitral commisurotomy, 
open mitral commisurotomy or mitral valve replacement  )or percutaneous  interventional  management 
(Balloon mitral valvuloplasty ) are the standard mode of treatment.
               In patients in whom the mitral valve is pliable (Wilkins score <8, No commissural calcium or  
severe sub valvular disease) management is relatively simple.
  When facilities are available, Balloon mitral valvuloplasty is the treatment of choice.  If expertise is 
not  available  or  the  cost  of  procedure  is  prohibitive,  then  closed  mitral  commissurotomy  is  the 
procedure of choice.
              Closed mitral commissurotomy is a relatively simple, cheap, effective surgical procedure with  
low complication rate and high success rate in experienced hands.
              Both the procedures needs left atrial and LA appendage thrombus ruled out by transesophageal  
echocardiograpy before performance.
            Systemic embolization is a devastating complication that occurs 0.5 to 3.3 % of patients 
undergoing BMV, the major cause is LA thrombus dislodged during catheter manipulation.
              The risk of this complication can be minimized by using TEE to evaluate for left atrial and  
appendage thrombus prior to the procedure .TEE should be performed within few days prior to the 
procedure, as otherwise thrombus may have formed in the interim.
               If thrombus is present, the recommended approach is that the procedure should be postponed,  
adequate oral  anticoagulation should be  instituted  for  at  least  2  to  3 weeks,  and TEE repeated  to 
demonstrate resolution of thrombus.
  If  the  thrombus  persists,  some clinicians  think  balloon  valvuloplasty is  safe  if  the  thrombus  is 
confined to LA appendage.  However most clinicians would recommend an open surgical procedure 
with clot removal.
             Similarly closed mitral  commissurotomy cannot be safely performed if  LA appendage 
thrombus is present, since this procedure involves introduction of finger through the LA appendage to 
assess the mitral valve, hence necessitating open mitral valvulotomy with clot removal.
             Open mitral valvotomy carries higher surgical risk, costly and needs cardiopulmonary 
bypass.
             Hence it seems prudent that in patients with valve anatomy suitable for BMV /CMC, a 
trial of oral anticoagulation may be initiated if patient is not overtly symptomatic, and look for 
clot  resolution.  If  clot  resolution  is  confirmed  by  TEE,  these  patients  may  be  benefited  by 
performing low risk BMV or CMC. 
        Only few studies15-19 available regarding this issue .Most of the studies conclude that LA body 
thrombus resolution is poor and most patients need open procedure.
         Many of those studies conclude that thrombus confined to LA appendage resolve with adequate 
anticoagulation for a period of 4 weeks to 6 months.
      Our study is aimed to study the effect of oral anticoagulation on left atrial appendage thrombus 
resolution in our population and to analyse various factors associated with resolution or reduction in 
size of left atrial appendage thrombus.
           ACITROM-ACENOCOUMAROL –Is the oral anticoagulant used in this study. It is the oral 
anticoagulant widely available and commonly used drug in our institution.
                    Its action as well as side effect profiles are   similar to warfarin sodium .It acts by 
inhibiting Vitamin K reductase enzyme, thereby prevents activation of Vitamin K which in turn is 
essential for activation of Vitamin K dependant coagulation factors involved in coagulation cascade, 
thereby exhibiting anticoagulant action
MECHANISM OF ACTION OF WARFARIN
                The vitamin K cycle and its link to carboxylation of glutamic acid resides on vitamin K 
dependant coagulation proteins. Vitamin K1 obtained from food sources is reduced to vitamin KH2 by 
a warfarin resistant vitamin K reductase. Vitamin KH2 is then oxidized to vitamin epoxide (vit KO) in 
a reaction that is coupled to carboxylation of glutamic acid residues on coagulation factors. 
             This carboxylation step renders the coagulation factors II, VII, IX, and X and the anticoagulant  
factors protein C and proteins functionally   active. Vit KO is then reduced to vit K1 in a reaction 
catalysed by vitamin KO reductase. By inhibiting vitamin KO reductase, warfarin blocks the formation 
of vitamin K1 and vitamin KH2, thereby removing the substrate (vitamin KH2) for the carboxylation of 
glutamic acid.
       Vitamin K1, either given therapeutically, or derived from food sources can overcome the effect of  
warfarin by bypassing the warfarin sensitive vitamin KO reductase step in the formation of vitamin 
KH2.
REVIEW OF LITERATURE
                   
              The predictors of thromboembolism in MS , is the present focus of interest , There is no 
correlation in  MS  , between the risk of embolism and NYHA functional cardiac status , MV area , MV 
calcification , and duration of AF.
             The tendency for embolisation in MS correlates directly with the age of the patient, size of the 
LAA, and indirectly with the cardiac output. MS patients more than 35 years of age, with dilatation of 
LAA,  and  with  low  cardiac  output  are  at  the  highest  risk  of  emboli.  In  a  recent  retrospective 
generalized  study  with  TEE,  it  was  observed  that  MS,  LA dilatation  and  severe  left  ventricular 
dysfunction , are independent risk factors for LAA thrombus formation. In addition, atrial fibrillation 
and  left  atrial  spontaneous  echo  contrast  have  been  associated  with  increased  risk  of  cardiogenic 
embolism in MS
              Gaswami et al9 prospectively   investigated various clinical and echocardiographic variables 
to predict the left atrial and left atrial appendage clot and spontaneous echo contrast in patients with 
severe rheumatic mitral stenosis.  They studied 200 consecutive patients (112 males and 88 females; 
mean age 29.6±9.6 years). Left atrial clot and spontaneous echo contrast were present in 26 and 53.5% 
of cases, respectively. There were no significant differences in the mitral valve area, mean transmitral  
diastolic gradient and left ventricular ejection fraction between patients with and without clot. 
Patients with clot were older (34.4±11.4 vs. 28.2±8.5 years, P<0.001), had longer duration of 
symptoms  (41.  4±36.0  vs.  28.8±22.9  months,  P<0.001),  more  frequent  atrial  fibrillation  and 
spontaneous echo contrast (69.2 vs. 16.9%, P<0. 00001 and 76.9 vs. 45.3%, P<0.00001, respectively) 
and larger left atrial area and diameter (41.0±12.7 vs. 29.9±7.4 cm(2), P<0.00001 and 53.9±8.3 vs. 
47.6±7.4 mm, P<0.0001, respectively) as compared to patients without clot. Similarly patients with 
spontaneous echo contrast were older (31±10.4 vs. 27.8±8.3 years, P<0.01), had more frequent atrial 
fibrillation (48.6 vs. 9.7%, P<0.0001), left atrial clot (37.4 vs. 12.9%, P<0.0001), larger left atrial area 
and diameter (37.6±11.2 vs. 28.1±6.7 cm(2), P<0.00001 and 52.2±8.3 vs. 45.9±6.5 mm, P<0.00001, 
respectively)  and smaller  mitral  valve  area  (0.77±0.14 vs.  0.84±0.13 cm,  P<0.01)  as  compared to 
patients without spontaneous echo contrast.
                 There were no significant differences in the mean transmitral diastolic gradient and left  
ventricular  ejection  fraction.  On  multiple  regression  and  discriminant  function  analysis,  atrial 
fibrillation and left atrial area were independent predictors of left atrial clot formation. In a subgroup of 
patients  with  sinus  rhythm, larger  left  atrial  area  and presence  of  spontaneous echo contrast  were 
significantly associated with the presence of clot in left atrium and appendage. 
               They concluded that in patients with severe mitral stenosis, the presence of atrial fibrillation  
and in the subgroup of the patients with sinus rhythm the presence of large left atrium (> or =40 cm 
and spontaneous echo contrast were associated with higher risk of clot formation in the left atrium and 
might be benefited by prophylactic anticoagulation.
             Gonzalez-Torrecilla E et al10    investigated the independent factors associated with the 
presence of left atrial (LA) spontaneous echo contrast (SEC) and thromboembolic events in patients 
with mitral stenosis (MS) in chronic atrial fibrillation (AF)  Transesophageal and transthoracic echo 
studies  were  performed  in  129  patients  with  MS  in  chronic  AF.  Previous  embolic  events  were 
documented in 45 patients, 20 of them within 6 months,  and 65 patients were receiving long-term 
anticoagulation. The intensity of LASEC and mitral regurgitation, the presence of thrombi and active 
LA appendage flow (peak velocities > or = 20 cm/s), and LA volume as well as other conventional 
echo-Doppler determinations were investigated in every patient. The prevalence of significant LASEC 
(degrees 3+ and 4+), thrombus, active LA appendage flow, and significant mitral regurgitation (>2+) 
were: 52% (67 patients), 29.5% (38 patients), 32% (41 patients), and 36% (47 patients), respectively. 
Multivariate  analysis  showed  that  decreasing  mitral  regurgitation  severity,  absence  of  active  LA 
appendage flow, and mitral valve area were the independent correlates of LASEC (odds ratio [OR] 3.7,  
5.4, and 0.17, respectively; all p <0.02). Active LA appendage flow and anticoagulant therapy were 
associated negatively, whereas the severity of LASEC was associated positively with the finding of LA 
thrombus (OR 9.6,  3.9,  and 1.6,  respectively;  all  p <0.05).  The intensity of  LASEC and previous 
anticoagulant therapy (OR 1.74 and 4.5, respectively; p <0.005) were the independent covariates of 
thrombi and/or recent embolic events. 
In conclusion, the severity of mitral regurgitation and lack of active LA appendage flow were, 
respectively, the strongest independent correlates of significant LASEC and thrombus in patients with 
MS in chronic AF. LASEC remains the cardiac factor most strongly associated with thrombus and/or 
recent embolic events in these patients.
              Acarturk E et al11  studied the thromboembolism risk in patients with mitral stenosis.They 
evaluated  a  total  of  168  consecutive  patients  with  predominant  rheumatic  mitral  stenosis  by 
transthoracic (TTE) and transesophageal echocardiography (TEE). Of the 168 patients, 35 had previous 
embolic events (group I) and 133 had no emboli (group II). A total of 77 (45.8%) patients had atrial  
fibrillation. The frequency of atrial fibrillation was higher in group I than group II (68.6% vs. 39.8%, p  
< 0.001). The incidence of left atrial enlargement was greater in group I (p < 0.001). Mitral valve area  
was found to be smaller in group I compared to group II (p < 0.001). In group I 83.3% and 29.2% of 
the  patients  with  atrial  fibrillation  had  left  atrial  spontaneous  echo  contrast  (SEC)  and  left  atrial 
thrombus, respectively, and 72.7% of the patients with sinus rhythm had left atrial SEC. In group II  
79.2% and 20.8% of the patients with atrial fibrillation had left atrial SEC and left atrial thrombus  
whereas 28.6% and 2.6% of the patients with sinus rhythm had left atrial SEC and left atrial thrombus, 
respectively. 
                The incidence of left atrial thrombus was significantly different in those patients with 
compared to those without embolic events (20% vs. 9.7%, p < 0.01).
In groups I and II, 28 of 35 (80%) and 64 of 133 (48.1%) patients had left atrial SEC (p < 0.01). 
Patients with left atrial SEC had a greater left atrial size (p < 0.01) and smaller 
mitral valve area (p < 0.01). Left atrial size was normal in 2 patients with left atrial SEC and 
SEC was  not  found in  55  patients  with  enlarged  left  atrium.  Multiple  logistic  regression  analysis 
showed that atrial fibrillation, mitral valve area and left atrial enlargement were independent predictors 
of the SEC (p < 0.001) and left atrial SEC was the principal determinant of thromboembolism. 
                They concluded thatt that regardless of rhythm and atrial size, left atrial SEC is a principal  
determinant of thromboembolic risk in mitral stenosis and suggested that TEE may be able to detect  
those patients with mitral stenosis at risk for emboli and guide appropriate therapy
                S J Saidi et al12   studied the incidence and factors influencing left atrial clot in patients with 
mitral   stenosis  and normal  sinus  rhythm.  In  their  study,  no  meaningful  relation  was  found 
between left atrial size and the presence of a clot in the left atrium, or between age and clot  
formation. On the other hand, despite the fact that the mean mitral valve score in the MS group in 
NSR with a clot was higher than the group without a clot, the difference was not significant. 
Another result of this study was the comparison of clot frequency in patients in NSR with those 
in AF rhythm. Clotting was more common in the AF group, with the difference being significant, 
as could be expected. Age of the patients in AF rhythm in that study was significantly higher than 
the group in NSR. 
Concerning the left  atrial  size,  mitral  valve score and valve  gradient,  obtained values  were 
significantly higher in the AF group compared to the group in NSR. Also concerning the coexistence of 
MR with MS and its effect on inhibiting clot formation,  their  study showed a lower percentage of 
clotting in the combined pathology (MS and MR) group compared to the pure MS group, although  the 
difference was not significant. This could be because the  MR present in the majority of the patients in 
this study was of mild severity. 
                They concluded that despite the fact that left atrial clot is usually sought in  MS patients with 
AF rhythm; MS patients in NSR are also at risk from intra-atrial clot formation. Although this risk is 
less than the AF rhythm group, it is sufficient to warrant measures for prevention of thromboembolic 
episodes in this group of patients. 
               Leung et al13 performed transesophageal echocardiograms in 2.894 patients over a 6.5 year 
period. They found 94 patients (3.2 %) to have left atrial thrombus. The thrombi were considered as 
mobile in 45 patients .Seventeen patients had suffered from a stroke or embolic event (event rate: 
10.4% per year) and 27 had died (mortality: 15.8% per year) during a follow-up period of 19.2 months. 
            Thirty-three  patients  had thrombus  with  a  maximum dimension ≥  1.5  cm.  Thrombus  
dimension≥ 1.5 cm, history of thromboembolism and mobile thrombus were considered as predictors 
of subsequent embolic events. 
ORAL ANTICOAGULATION IN LEFT ATRIAL APPENDAGE THROMBUS
         Only limited literatures are available which studied the effect of oral anticoagulation on left atrial 
thrombus resolution. Most of the studies suggest left atrial body thrombus resolves poorly with oral 
anticoagulation .Left atrial appendage thrombus resolves variably in different studies.   The standard 
treatment for left atrial thrombi once identified is anticoagulation with heparin and/or warfarin. The 
rational of anticoagulation therapy is to prevent further increase of existing thrombi and emboligenic 
material formation on the surface of an existing thrombus.
             Silaruks S et  al14    studied  the  resolution  of  left  atrial  thrombus  after 6 months  of 
anticoagulation in candidates for percutaneous transvenous mitral commissurotomy .They have used 
oral warfarin sodium for 219 potential candidates for percutaneous mitral commissurotomy (PTMC) 
with  left  atrial  thrombus  (mean  age  39.6  (7.4)  years).Complete  resolution  of  thrombus  was 
demonstrated in 53 patients (24.2%), who subsequently underwent successful PTMC. In another 166 
patients, the thrombus size was reduced by 24% (p < 0.001) .No thrombus resolution was observed in  
the 27 patients with a left atrial body thrombus. Eighteen patients had minor bleeding.
The significant predictors of thrombus resolution were a New  York Heart Association functional class 
II, a left atrial appendage thrombus size 1.6 cm2,
 a left atrial spontaneous echocardiographic contrast grade of 1, and an international normalised ratio 
(INR) of at least 2.5. Patients with all of these predictors had a 94.4% chance of complete thrombus 
resolution (95% CI 84.4% to 98.1%).
              Jaber WA et al15 similarly studied efficacy of anticoagulation in resolving left atrial and left 
atrial  appendage  thrombi  by using   transesophgeal  echocardiography,  concluded  that  a  significant 
number of patients with LA appendage thrombus undergo resolution over long term anticoagulation.
              Corrado et al16 concluded that the anticoagulation therapy was associated with resolution of 
atrial thrombi in the majority (81.8%) of patients presented with atrial fibrillation of recent onset.
               Kandpal et al17. showed that 41.7% of isolated LA appendage clots resolved in contrast to 
12.5% of LA body clots in patients with mitral stenosis after 6months of oral anticoagulation.
                Recently J Srimannarayana et al18 studied the occurrence of left atrial body and left atrial 
appendage clots in patients with rheumatic mitral stenosis and atrial fibrillation, and to document the 
effect of long-term anticoagulation on clot dissolution.
They selected consecutive patients with severe rheumatic mitral stenosis and atrial fibrillation and they 
were assessed by transesophageal echocardiography. Those with left atrial body or left atrial appendage 
clots were anticoagulated with oral nicoumalone.
Transesophageal  echocardiography was  then  repeated  in  patients  on  anticoagulation  who  were  on 
regular  follow-up,  and  in  whom  percutaneous  transvenous  mitral  commissurotomy  could  be 
considered. Of the 490 patients studied, 163 had left atrial body or left atrial appendage clots. A repeat 
transesophageal  echocardiographic  examination  was  done  in  50  patients  who  had  optimal 
anticoagulation for a period of 6 months.   Only 2 of the 17 patients who had left atrial body clots had 
successful  clot  dissolution  after  long-term  anticoagulation,  while  the  left  atrial  appendage  clots 
disappeared in 31 of 33 patients (p<0.001).
             They concluded that left atrial clots are present in a third of patients with severe rheumatic 
mitral stenosis and atrial fibrillation and isolated left atrial appendage clots in patients with rheumatic 
mitral stenosis and atrial fibrillation can disappear with long-term anticoagulation, while thrombi that 
extend into the left atrial body may persist despite optimal anticoagulation.
               Murillo et al19. showed that PTMC can be performed in patients with an LA appendage clot 
with TEE guidance and fluoroscopic control. However, this can be fraught with the risk of embolism. 
Hence, the interventional cardiologist will always prefer the LA and LA appendage to be free of clots 
before embarking on balloon mitral valvotomy.  
STUDY DESIGN AND METHODOLOGY
This study was performed in the year 2005 in the Department of Cardiology, Madras Medical College 
and Government General Hospital, Chennai.
 INCLUSION CRITERIA
          1. Patients with severe isolated mitral stenosis with valve anatomy suitable 
          for  PTMC/CMC
          2. No significant lesions in other valves (mild or less only selected) except for Tricupid 
regurgitation secondary to Pulmonary hypertension.
          3. NYHA Class I-III status.
          4.  Patients newly started oral anticoagulation,  with no significant oral    anticoagulation  
previously. 
 EXCLUSION CRITERIA
         1. Patients with NYHA class IV status.
         2. Moderate to severe calcification of mitral valve
         3. Left atrial body thrombus.
         4. Significant other valve involvement (more than mild) including significant 
         mitral regurgitation.
         5. Significant co-morbid conditions.
         6. Previous cardiac surgery including closed mitral commissurotomy.    
          7. Pregnancy and puerperium.
          8. Those patients who did not give consent for the study.
          
               Sixty patients who met the inclusion criteria are screened for left atrial appendage  thrombus  
by    TEE.  Thirty  patients  with  severe  mitral  stenosis  who 
showed evidence of left atrial appendage thrombus by transoesophageal echocardiography and who 
gave consent for the study were selected for the study. Five   patients who lost follow-up were excluded 
from the study.
               Informed consent was obtained from all the patients after explaining the study.
A  thorough  history  including  NYHA  status  of  breathlessness,  orthopnoea,  PND,  H/O 
thromboembolism, peripheral  oedema, chest pain,  palpitations,  haemoptysis  and previous treatment 
details were obtained.
           Complete physical examination was done in all patients. A 12 lead electrocardiogram and chest 
X-ray were taken routinely. Repeat ECGs were taken as and when needed.
          The study group included 25 patients (16 female and 9 male) aged between 22 to 44 years (mean 
32.2 yrs).All patients had definite evidence of  left atrial appendage thrombus by TEE.
            20 patients were in atrial fibrillation (including 3 patients in intermittent atrial fibrillation) and 5 
patients were in sinus rhythm during the study.
ECHOCARDIOGRAPHIC DATA
          A complete Transthoracic echocardiogram was obtained including M- mode, 2D, colour Doppler 
and pulse& continuous wave Doppler in every patient.
ALOKA Trivitron  model  echo  machine  was  used  for  this  study.  A 2.5  MHZ probe was  used  for 
transthoracic  echocardiography  and  a  5  MHZ  multiplane  probe  was  used  for  transesophageal 
echocardiography.
           Lesion severity in individual valve was characterised by various methods.
           Specific attention was paid in assessing mitral valve morphology, Wilkin’s scoring, mitral valve 
area by planimetry & pressure half time method, peak and mean transmitral gradient.  
M-mode echocardiogram with cube formula was used to assess global LV systolic function. M-mode 
echocardiogram at mitral & aortic valve level was obtained routinely for measurement.
          Left atrial dimensions were measured in end systole in PLAX- antero posterior  (D1)and two  
orthogonal diameters in four chamber view(D2 &D3 ) and left  atrial  volume calculated by prolate 
ellipse method.
          Left atrial volume = (D1 X D2 X D3) X 0.523
          A note on spontaneous echo contrast in left atrium was made. Its severity graded as 
  Grade 1-Mild, Grade 2 –Marked.
Left  atrial  appendage  was  visualised  in  PSAX  view  at  aortic  valve  level  and  LAA thrombus  is 
characterized  by  measuring  its  major  and  minor  dimensions.  A  focused  transoesophageal 
echocardiogram was obtained for all patients.
             Multiple views were used to visualise the entire left atrium for identifying evidence of thrombi  
by TEE. 
            Left atrial appendage was visualised thoroughly in multiple planes.                         LA  
appendage was examined in at least two orthogonal views .A basal short axis view at approximately 45 
* and a more vertical plane 90-120 * with leftward rotation of probe were used to visualise it.
         Care  was  taken  to  distinguish  normal  trabeculation  from localised  thrombus  formation.  
Trabeculae tend to be more linear and are continuous with the atrial wall in 
more than one view. Thrombi typically protrude into the appendage, often with independent motion.
         Once visualised thrombi is assessed for size, mobility and whether it extends to body of the left  
atrium. Size of the thrombus is measured as major and minor dimensions.
  LA appendage area in diastole & systole were measured and LAA ejection fraction calculated using 
formula;
               LAA EF (%) = (LAA.max –LAA .min)/LAA. max X   100
(LAA.max-Maximal LAA area (end atrial diastole), LAA.Min.- Minimum area (end atrial systole)- by 
planimetry.)
            
Left  atrial  appendage  function  was  assessed  using  pulsed  Doppler  imaging,  with  sample  volume 
positoned at mouth of the appendage; the maximal velocity during atrial contraction was measured. 
This velocity corresponds to the force of atrial appendage contraction or emptying.
Pulmonary venous pulsed wave Doppler was obtained from left upper lobe pulmonary vein. Entire left 
atrium was searched for thrombus and specific note was made on mitral valve morphology and left 
atrial spontaneous echo contrast. 
           All patients received standard medical treatment with, Digoxin, Penicillin, Pottasium chloride 
syrup, Verapamil, Diuretics and other drugs according to the clinical condition.     
          Oral anticoagulation started in all patients with 2 -3 mg of Acitrom(Acenocoumorol) once daily.  
Dose  adjustments  were  made  weekly  by  monitoring  Prothrombin  time  and  INR  (International 
normalised ratio).
           INR was maintained between 2-3. Patients were followed up weekly by monitoring any 
symptom change, bleeding, thromboembolic episode, and prothrombin time and INR measured. Fresh 
ECGs were taken when clinical suspicion of change in rhythm was noted.
         Oral anticoagulation was continued for 6 weeks..
          Focussed transthoracic and transesophageal echocardiogram was repeated after 6 weeks and the 
important parameters were collected. Left atrial appendage thrombus presence/absence, and if LAA 
thrombus was present, its size in major and minor dimensions were measured in both TTE and TEE.
           A note on LA spontaneous echocontrast was made.
         All the data collected were subjected to statistical analysis and conclusion derived.  
STATISTICAL ANALYSIS
        Continuous variables were expressed as mean values with standard deviation, while proportions  
were presented as numbers and percentages of the total. The significance of differences between means 
was tested by the Student’s t test, while that between proportions was tested with the Chi-square test. A 
p value <0.05 was considered significant. 
OBSERVATIONS AND RESULTS
             This study involved twenty five patients (16- female; 9- male) aged between 22 to 44 years  
(Mean 32.2 ± 6.4 years).Among these patients 17 patients were in atrial fibrillation and 5 patients 
remained in sinus rhythm throughout the study. Three patients who were in AF during start of the study 
showed intermittent sinus rhythm during follow-up.
             All the patients had severe mitral stenosis with mean mitral valve area by pressure half time  
method was 0.62 ± 0.11 sq.cm and mean and peak gradient 15.4±1.95 and 24.65 ± 2.98 mm Hg.. Mitral 
regurgitation was mild in 14 patients and trivial in 11 patients.
            None of the patients had significant aortic valve disease (3-patients had mild aortic stenosis and  
8-patients  had  mild  aortic  regurgitation).None  of  the  patients  had  significant  tricuspid  stenosis. 
Tricuspid regurgitation secondary to pulmonary hypertension was present in all patients .7 patients had 
severe  TR,  5  patients  had  moderate  TR  and  remaining  13  patients  had  mild  TR.  Pulmonary 
hypertension secondary to mitral stenosis was severe in 10 patients and moderate in 12 patients and 
mild in 3 patients.
         The Wilkin’s score ranged between 5 to 9 with Mean ± SD was 7.32±1.1. Left atrial dimension in  
parasternal long axis at aortic valve level was 5.86 ±0.56 cm. LA volume calculated by prolate ellipse 
method was 151.05 ±40.27 ml.
          All patients showed evidence of left atrial spontaneous echo-contrast (LASEC).Eleven patients 
were graded to have Mild LASEC and fourteen patients had ble change in the marked LASEC.   LA 
appendage was dilated in all patients with maximum area by planimetry method ranged between 3.8 cm 
2 to 7.35 cm 2, mean± SD (5.32 ±0.77 cm2).
           Average LA appendage ejection fraction was 19.20±8.4 % in the study group  and markedly  
differed  between  sinus  rhythm group  and  atrial  fibrillation  group.  In  sinus  rhythm LAA ejection 
fraction was 31.52± 7.9 % and in those with AF it was 16.1± 5.13%.  LA appendage emptying velocity 
ranged between 7 cm /sec to 50 cm/sec with mean ± SD   17.9± 11.7 cm/sec, which  also differed  
significantly  between two groups .In atrial fibrillation group LAA-EF was 12.63±4.95 cm/sec and in 
sinus rhythm group it was 39 ± 2.6 cm/sec.
            LA appendage thrombus was present in all patients. Their major and minor dimensions ranged  
between 1.2x1.1 cm to 4.7 x 2.1 cm.
            The dose of Acitrom needed ranged between 2 to 4 mg / daily, and all patients were maintained 
with INR 2 to 3 over a mean period of 3 weeks. None of the patients reported significant symptom 
change or any history suggestive of thromboembolic episode during 6 weeks follow-up.On serial ECGs 
3 patients showed sinus rhythm intermittently. All of them were in  atrial fibrillation on 6th week .
            Focussed TEE done at 6th week showed complete resolution of LA appendage thrombus 
resolved in four patients and more than 30% reduction in size of thrombus in four patients. In the 
remaining 17 patients  there were no significant  changes in  the size of  the thrombus.  None of  the 
patients showed significant increase in size of the thrombus.
           Repeat objective reassessment of left atrial spontaneous echo-contrast was done. None of the  
patients showed any notagrade of LASEC
                                   BASELINE CHARECTERISTICS
Characteristic
s
Number
Sex
Male
Female
9
16
Age group
<30 yrs
30-40 yrs
>40 yrs
6
15
4
Rhythm
SR
AF
Intermittent AF
5
17
3
MR
Trivial
Mild
14
11
PHT
Mild
Moderate
3
12
Severe 10
LASEC Grade
Mild(I)
Marked(II)
11
14
                                     
BASELINE CHARACTERISTICS
Baseline Characteristics Mean± SD
Mitral valve area (cm2)      0.62±0.11
LA dimension(PLAX) ( cm)      5.86±0.56
LA volume           (ml)      151.06±40.27
Mean gradient   (mm Hg)      15.4±1.95
Peak gradient  (mm Hg)      24.65±2.98
Wilkin’s score      7.32±1.1
LAA area-Maximum (cm2)      5.32±0.77
LAA-Ejection fraction (%)
Over all  
LAA -EF-In SR 
LAA-EF-In AF       
     19.20±8.4
      31.52±7.9
     16.12±5.1
LAA-emptying velocity(cm/sec)
Over all
In SR
In AF
      17.9±11.7
       39±2.6
      12.63±4.95
RESULTS
Resolution of Left atrial appendage thrombus occurred in 16% (4) of the individuals. Reduction in size 
of more than 30%was seen in 16% (4) patients.
Remaining 68% (17)  of  the  patients  showed no significant  change in  thrombus size.  None of  the 
patients  showed  significant  symptom  change  or  thromboembolic  episode  or  any  bleeding.  No 
significant change in grading of LASEC was noted in any of the patients. 
SUB GROUP ANALYSIS
                    LAA thrombus resolution or reduction in size occurred in 66.6% of patients in the age 
group of <30 years and in 26.6% of patients in the age group of 30 to 40 years. None of the patients 
above 40 years of age had any resolution or reduction in size of the thrombus. The mean age of patients 
who showed complete resolution was 27.25 years as against 34.05 years  in patients with no resolution.
                     Similarly 60% of patients in sinus rhythm and 66.6 % of patients with 
intermittent AF showed resolution or reduction in size of the study. But only 11.6% 
of patients with atrial fibrillation showed resolution or reduction in size and 88.4% of patients with 
atrial fibrillation showed no or minimal change in thrombus size.
               All the patients who showed complete thrombus resolution had thrombus dimension less than  
1.5 cm in major axis. Among the patients with thrombus dimensions > 1.5 cm size, none of them 
showed complete resolution and only 13.3% showed significant reduction in size.
There is no significant difference in mitral valye area among the three groups. Mean Wilkin’s score was 
significantly lower in patients who had thrombus resolution as against those without resolution (6.5 vs 
7.47).Patients showing no change in thrombus dimension had significantly higher left atrial dimensions 
and volume.
Patients who showed resolution of thrombus had significantly higher LAA ejection fraction compared 
with those showing no change in thrombus dimensions.   (28 ± 0.12 vs 
15.86 ± 0. 06)
Similarly  patients  who  had  resolution  of  thrombus  had  significantly  higher  LAA peak  emptying 
velocity compared with those without any change. (32.5 ± 14.1 cm/sec.  vs 12.45 ± 5.96 cm/sec.)
                                                               RESULTS
               Age(yrs) Rhythm
Clot Size(major 
dimension) LAA Emptying Velocity
<30 (6)
30-40 
(15) >40 (4)
AF 
(17) AF-I (3)
SR 
(5)
<1.5cm 
(10)
   >1.5cm 
(15)
<30 cm/s 
(19) >30 cm/s (6)
Resolution
(2)
33.3%
(2)
13.3%
(0) (1)
5.8%
(1)
33.3 %
(2)
40%
(4)
40%
(0) (0) (4)
66.6%
>30% Size 
Reduction
(2)
33.3%
(2)
13.3%
(0) (1)
5.8%
(1)
33.3%
(2)
40%
(2)
20%
(2)
 13.3%
(2)  
10%
(2)
33.4%
No / Minimal 
Change
(2)
33.3%
(11)
73.3%
        (4)
100%
(15)
88.4%
(1)
33.3%
(1)
20%
(4)
40% (13) 88.7%
(17) 
90%
0
                                                  
                                                SUB GROUP ANALYSIS
Characteristics Resolution Reduction No change  P value
(Resolution
vs No change)
Age(Yrs) 27.25±6.4 30±7.6 34.05±5.6 < 0.001
Sex
Male
Female
2                                    
2
1
4
6
10
  0.1
NS
Rhythm
SR
AF
AF-I
2
1
1
2
1
1
1
15
1
  SR vs AF
<0.0001
Wilkins’s score 6.5±1 7.5±1.29 7.47±1.06 <0.01
LA dimension(cm) 5.67±0.68 5.6±0.59 5.97±0.52 <0.01
LA volume( ml) 138.95±56.2 146.25±26.0 155.05±39.9 <0.02
LAA-EF(%) 28±0.12 24.93±0.05 15.86±0.06 <0.001
LAA empt. Vel.(cm/sec) 32.5±14.1 26.5±14.66 12.45±5.96 <0.001
Mitral valve area 0.63±0.12 0.60±0.12 0.62±0.1 0.5 NS
Thrombus size
Less than 1.5 cm
More than 1.5 cm
4
0
2
2
4
13
<0.0001
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                              The chance of clot resolution reduces with age
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 No. of patients
Resolution Reduction No change
Thrombus change P<0.0001 (Sinus rhythm vs AF for 
clot resolution)
RHYTHM
Sinus rhythm
Intermittent AF
AF
Sinus rhythm favours thrombus resolution, whereas persistant AF is associated with poor resolution
MITRAL VALVE AREA
0.585
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0.595
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Resolution Reduction No change
Thrombus change   P=0.5  NS (Resolution vs No change)
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There is no significant correlation between mitral valve area and resolution of LA thrombus.
WILKIN'S SCORE
6
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7
7.2
7.4
7.6
Resolution Reduction No change
Thrombus change P<0.01(Resolution vs No change)
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                 Higher Wilkin’s score is associated with lower clot resolution
LA Dimension (cm)
5.4
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6
Resolution Reduction No Change
Thrombus change              p < 0.01   (Resolution vs No 
change)
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LA VOLUME
130
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Resolution Reduction No change
Thrombus change  P<0.02(Resolution vs No change)
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LA dimensions  and  volume  were  significantly  larger  in  those  with  no  resolution  compared  with  those  with 
resolution.
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Patients who showed thrombus resolution had significantly higher LAA –EF compared to those who did not show 
any change.
LAA PEAK  EMPTYING VELOCITY
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Reduction in LAA peak emptying velocity was associated with reduction or failure of thrombus resolution 
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Thrombus change 
P<0.0001(Resolution vs No 
change)
THROMBUS SIZE
<1.5 cm
>1.5 cm
Thrombus size significantly influences resolution. Those with  < 1.5 cm size resolves rapidly as 
against those with   size > 1.5 cm, which were associated with poor resolution
DISCUSSION
           Anticoagulation is conventionally used to reduce the risk of the thromboembolic events  
associated  with  AF.  Oral  anticoagulants  act  by  inhibiting  the  synthesis  of  vitamin  K-dependent 
coagulation factors. This prevents new thrombus formation, and promotes adherence and organization 
of old thrombi to the surrounding endocardium. 
           However, recent studies have supported an alternative hypothesis of benefit that includes not  
only the prevention of new thrombus formation but also the resolution of existing thrombi. 
          In situations in which a thrombus is already present, anticoagulation prevents further thrombus 
extension, thereby facilitating the action of endogenous fibrinolysis.
             A study conducted by Kandpal et al.  showed that 41.7% of isolated LA appendage clots 
resolved in contrast to 12.5% of LA body clots in patients with mitral stenosis after 6 months of oral  
anticoagulation. Resolution of atrial thrombi after oral anticoagulation in patients with non- valvular 
AF has also been examined in several studies. 
               In the present study, we have analyzed factors associated with resolution of LA appendage 
thrombus with oral anticoagulation.
Older age (>40 years) was not only associated with increased prevalence of left atrial thrombus but also 
with failure of thrombus resolution with anticoagulation.
Similarly presence of atrial fibrillation favors stasis and abnormal low velocity flow patterns in the left 
atrium and  appendage  associated  with  failure  of  thrombus  resolution.  Left  atrial  appendage  peak 
emptying velocity and LAA ejection fraction were significantly lower in patients with atrial fibrillation 
and are associated with failure of thrombus resolution.
On the other hand patients with sinus rhythm had significantly higher LAA peak emptying velocity and 
LAA ejection fraction and associated with better resolution or reduction in thrombus size.
From the above observations it seems prudent that intact mechanical function of left atrial appendage 
facilitates the action of oral anticoagulants on the thrombus and resulting in resolution. 
Patients with smaller thrombus size (<1.5 cm) showed better resolution compared with larger thrombus 
size. This difference is possibly explained by the fact that a higher thrombus burden does not permit 
dissolution  with  endogenous  fibrinolysis  despite  optimal  anticoagulation  and  with  much  smaller 
thrombus burden, allows dissolution by endogenous fibrinolysis, while effective oral anticoagulation 
prevents fresh thrombus formation.
From the  above  observations  a  management  strategy  can  be  derived.  Stable  patients  with 
isolated severe mitral stenosis whose valve anatomy is suitable for balloon  mitral valvulotomy with 
isolated left atrial appendage thrombus can afford to be on adequate oral anticoagulation for a short 
period (6weeks to 6 months) if the thrombus is small especially if they are young and in sinus rhythm. 
If repeat TEE revealed thrombus resolution they can be subjected to balloon mitral valvotomy or closed 
mitral commissurotomy.
If the thrombus does not resolve they can be referred for open surgical procedure. 
On the other hand, older patients and those with large LA appendage thrombus or LA body thrombus 
can be straightaway referred for open surgical procedure with clot removal
LIMITATIONS OF THE STUDY
            This is a small non randomised study involving small number of selected patient group. The 
patient groups are treated for shorter period of time. Further, large-scale study with longer duration (6 
months) of follow up may be necessary to confirm the findings of our study.
CONCLUSION
        Adequate oral  anticoagulation (INR 2-3) is  effective in  resolution of  left  atrial  appendage 
thrombus in rheumatic mitral stenosis in a significant group of patients over a period of six weeks. The  
resolution is either complete or partial.
             Among patients receiving oral anticoagulation, 16% showed complete resolution of thrombus 
and another 16% showed more than 30% reduction in size of thrombus.
Factors associated with resolution or reduction in size include
              Younger age (<40 years)
             Small thrombus size (< 1.5 cm)
             Sinus rhythm,
             Intermittent atrial fibrillation 
             Left atrial appendage peak emptying velocity more than 30 cm/sec.
 Majority of patients showed no significant change in thrombus size.
              None of the patients showed significant (>30%) increase in size of the thrombus during the  
study period.
Factors associated with failure of resolution or reduction in size include
            Older age (> 40 years)
             Large initial thrombus size (> 1.5 cm)
             Persistent atrial fibrillation 
             Left atrial appendage peak emptying velocity less than 30 cm/sec 
             Larger left atrial dimensions and volume.
              None of the patients showed evidence of thromboembolic events or any bleeding complication 
during the study period.
              Oral anticoagulation did not show any notable change in spontaneous echo contrast in left  
atrium during the study period.
IMPLICATIONS OF THE STUDY 
Patients  with  rheumatic  mitral  stenosis  with  left  atrial  appendage  thrombus  who  have  valve 
morphology suitable for balloon mitral valvotomy or closed mitral commissurotomy can be subjected 
to adequate oral anticoagulation for thrombus resolution for a short period (6 to 8 weeks) if they are 
clinically stable. This is especially so if the patients are young, with smaller thrombus size, particularly 
if they are in sinus rhythm.
               If the thrombus resolves, management is simplified by doing balloon mitral valvotomy or  
closed mitral  commissurotomy,  instead  of  open mitral  valvotomy with  thrombus removal  in  those 
patients.
On the other hand older patients with large left atrial appendage thrombus can be straightaway referred 
for open surgery especially if  they are in atrial  fibrillation and low left  atrial  appendage emptying 
velocity.  
           
                PROFORMA FOR PATIENT’S DATA COLLECTION
ANTICOAGULATION IN RHEUMATIC MITRAL STENOSIS
WITH   LEFT ATRIAL  APPENDAGE THROMBUS  . 
Name                                    Age                      Sex                         Address
Symptoms     Dyspnoea                                   Class                                         Duration
                      Orthopnoea
                       PND
                       Palpitation                                 Class                                           Duration
                       Odema legs                                         
                       Thromboembolic phenomena                                                        Type 
                       Chest pain
                       Haemoptysis
                       Others 
Signs               Pulse                                           BP                      JVP               Apex 
 
                       S1                   A2                 P2                         OS                      MDM
                      Mitral systolic murmur                        TR                                
ECG
TRANSTHORACIC ECHOCARDIOGRAM
              Chamber dimensions & function 
    
                         LV                                                                    RV
                  
                         RA
              
               LA dimensions      A4C                PLAX                  PSAX
               LA area         
                                              
               LA volume
                    
              Wilkins score                         Valve thickness                 
                                                               Calcification
                                                               Mobility
                                                               Subvalvular disease 
                                                               Total
                            MR                                TR                                 PAP 
                           Other valves
  
                           Thrombus               Site                    Size              Character
                                                             LA
                                                            LAA
                           LA -SEC
TRANSOESOPHAGEAL ECHOCARDIOGRAPHY
                        LA appendage     Size                   Area                     LAA Function (EF)
               
                        LA-SEC
               
                        LAA Thrombus      Present                           Absent
                                                          Site                 
                                                          Size                                                                                
                                                         Character                              
                                                         Mobility
                      LA Appendage peak emptying velocity                          cms /sec
                      Left upper pulmonary vein flow Doppler 
                      
                       Any other interesting finding
Medical treatment
                       Digoxin                   Lasix                  Aldactone          Penicilln        KCL
                        Verapamil                         Others
Oral Anticoagulation;
                                        Acitrom(Acenocomorol)                    mgs OD daily
                               
Follow- up
Week 
        Symptom change    
                                                                                       ACITROM Dose change
        Bleeding
        Thromboembolic episode 
        Prothrombin time and INR
 
        Fresh ECG
Follow-up Echo       (6 weeks)
Transthoracic echo
                Any new finding
                            LA-SEC status
                           LAA-Thrombus Status                      
                             Size                   
                             Area         
                             Character
  Transesophageal echo
                            LA appendage area
                           Function
                           LA-SEC                 Status
                           LAA thrombus     Present                  Absent
                          Size                     
                          Area 
                          Character
                          LAA peak emptying velocity 
Miscellaneous.
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